ArticleLeukemia2015

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.

R B Walter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.